In future research and clinical practice, further exploration of the mechanisms of SGLT-2 inhibitors and long-term safety and efficacy evaluations in different populations and specific kidney diseases will be key to promoting their widespread use. This evidence concerns the gene SLC5A2 and kidney disorder.